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patients versus controls and a significantly lower cord/ma-
ternal plasma ratio. Other FA ratios studied were not differ-
ent between GDM and controls. A disturbed  13 C-DHA pla-
cental uptake occurred in GDM patients treated with diet or 
insulin, while the latter also had lower  13 C-DHA levels in the 
venous cord. The tracer study pointed towards an impaired 
placental DHA uptake as a critical step, while the transfer of 
other  13 C-FA was less affected. Patients with GDM treated 
with insulin could also have a greater fetal fat storage, which 
may have contributed to the reduced  13 C-DHA in the venous 
cord observed. The DHA transfer to the fetus was reduced in 
GDM pregnancies compared to controls. This might have an 
influence on fetal neurodevelopment and long-term conse-
quences for the child.  © 2014 S. Karger AG, Basel 
 Introduction 
 The increasing prevalence of obesity in the world is 
resulting in an increasing number of obese women of re-
productive age with an enhanced risk of developing ges-
tational diabetes mellitus (GDM) during pregnancy. Both 
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 Abstract 
 The functionality of the placenta may affect neonatal adipos-
ity and fetal levels of key nutrients such as long-chain poly-
unsaturated fatty acids. Fetal macrosomia and its complica-
tions may occur even in adequately controlled gestational 
diabetic (GDM) mothers, suggesting that maternal glycemia 
is not the only determinant of fetal glycemic status and well-
being. We studied in vivo the placental transfer of fatty acids 
(FA) labeled with stable isotopes administered to 11 control 
and 9 GDM pregnant women (6 treated with insulin). Sub-
jects received orally  13 C-palmitic,  13 C-oleic, and  13 C-linoleic 
acids and  13 C-docosahexaenoic acid ( 13 C-DHA) 12 h before 
an elective caesarean section. FA were quantified by gas 
chromatography and  13 C enrichments by gas chromatogra-
phy-isotope ratio mass spectrometry. The  13 C-FA concentra-
tion was higher in total lipids of maternal plasma in GDM 
patients versus controls, except for  13 C-DHA. Moreover,  13 C-
DHA showed a lower placenta/maternal plasma ratio in GDM 
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obesity and GDM are related to neonatal adiposity, and 
the placenta is a key organ mediating the materno-fetal 
nutrient transfer. The regulation of placental enzymes, 
receptors, and transport proteins determines the extent 
of glucose, lipid, and amino acid transfers to the fetus, 
which strongly contribute to fetal growth. Although im-
provements in prenatal care have significantly decreased 
the number of adverse outcomes, the mechanisms associ-
ated with fetal programming of obesity are under evalua-
tion, and placental tissue could have a key role in the pro-
cess of fetal growth and development. 
 Perinatal Risk Factors for Fetal Overgrowth 
 It is well recognized that maternal hyperglycemia plays 
an important role in the development of fetal macroso-
mia. The Pedersen hypothesis postulated that maternal 
hyperglycemia during pregnancy was transmitted to the 
fetus, which in turn produced and released large amounts 
of fetal insulin that promoted fetal overgrowth or macro-
somia  [1] . However, fetal macrosomia may occur even in 
adequately controlled GDM mothers  [2, 3] and in off-
spring of obese women with a normal glucose tolerance 
 [4, 5] , suggesting that maternal glycemia is not the only 
determinant of fetal glycemic status and well-being.
 Recent studies have reported that maternal pregesta-
tional obesity, even in women with well-controlled 
GDM, is also a very important determining factor for 
fetal growth and childhood obesity  [6] . Nevertheless, the 
pregestational maternal body mass index (BMI) is not a 
biological effector, and the mechanisms via which the 
BMI exerts its effect on fetal growth remain largely un-
known.
 The maternal BMI may modify the supply of nutrients 
by affecting the insulin resistance, which may contribute 
to maternal dyslipidemia, and a higher availability of en-
ergy substrates may contribute to the enhancement of fe-
tal fat transfer and deposition. Moreover, it may modify 
the cytokine and hormone environment, which may alter 
the placental structure and function, and it may even af-
fect the placental nutrient transport capacity, impacting 
neonatal adiposity. In fact, the placental structure is al-
tered in placentas of women with GDM, presenting no-
table increases in size and thickness  [7, 8] which are well 
recognized by obstetricians; in obese subjects, an increase 
in placental size also occurs, especially in severely obese 
mothers  [9] .
 In a multivariate analyses performed on healthy preg-
nancies from a subcohort (n = 207) of the STORK study 
in Norway, which focused on the determinants of fetal 
growth, it was shown that maternal BMI and fasting glu-
cose were independently associated with the newborn fat 
percentage  [10] . However, this effect disappeared when 
placental weight was introduced as a covariate. Those au-
thors suggested that the effect of the maternal BMI on 
fetal fat accretion acts, to a significant extent, by modify-
ing the placental weight  [10] .
 In a further evaluation of the STORK cohort including 
1,031 healthy pregnant women, the authors reported that 
the effect of maternal factors on placental weight was in-
fluenced by fetal sex; maternal glucose was significantly 
associated with placental weight in females but not in 
males  [11] . Recently, fetal sex-specific differences in the 
placenta have been identified in terms of gene expres-
sion, histological examination, and cytokine production 
 [12] .
 Thus, there is an emerging understanding of the phys-
iology linked to sex-specific effects on the placenta. It is 
also interesting to note that gestational weight gain in ear-
ly pregnancy (first half of the pregnancy) in such studies 
had a positive effect on placental weight. Maternal weight 
gain in early pregnancy is associated with a placental hor-
mone-driven increase in plasma volume and fat stores, 
making the association between early weight gain and 
placental mass biologically plausible  [11] .
 As in all healthy subjects, in normal pregnancies ma-
ternal insulin contributes to glucose homeostasis by im-
proving the peripheral glucose tissue uptake. However, 
the role of insulin in placental glucose transfer is limited 
since placental glucose uptake occurs via the glucose 
transporter GLUT-1, the activity of which is independent 
of insulin  [13] . 
 However, placental tissue displays insulin receptors, 
and activation may lead to a cascade of signals which reg-
ulate the nutrient sensor signal mTOR (mammalian tar-
get of rapamycin)  [14] . mTOR is a positive regulator of 
placental amino acid transporters and stimulates cell pro-
liferation and growth, promoting an anabolic metabolic 
phenotype. Preliminary studies have indicated an activa-
tion of placental mTORC1 signaling in association with 
maternal obesity  [15] and probably with GDM, which 
could be linked to higher insulin levels in these subjects. 
This could explain in part the greater size of GDM pla-
centas compared to those of normoglycemic individuals. 
Insulin resistance also enhances maternal free fatty acids 
(FA) and triglycerides, particularly in obese individuals. 
In this context, it is important to consider whether factors 
other than glucose modulate fetal overgrowth and adi-
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 Placental Lipid Transport 
 In normal pregnancies, during the third trimester there 
is a physiological insulin resistance that promotes mater-
nal lipolysis, producing hyperlipidemia to ensure triglyc-
erides and free FA for the fetus. In GDM pregnancies, this 
insulin resistance is exacerbated ( fig. 1 ). Although, there 
are discrepancies, the lipid metabolism is altered towards 
a more atherogenic lipid profile, with high levels of triglyc-
erides and low LDL cholesterol and reduced levels of HDL 
cholesterol  [16] . A relationship between maternal triglyc-
erides and nonesterified FA (NEFA) and fetal fat mass and 
neonatal body weight has been found in GDM, suggesting 
that an altered lipid metabolism is a risk factor for macro-
somia in affected women  [17] .
 In contrast to glucose, the role of lipids in the regula-
tion of fetal growth has received little attention. The pla-
cental transfer of FA is a complex process that involves 
several lipases and FA carriers  [18] . Lipid uptake requires 
the release of FA esterified within maternal lipoproteins. 
Lipoprotein lipase mainly hydrolyzes triglycerides, while 
endothelial lipase mainly hydrolyzes phospholipids, pro-
ducing NEFA. The liberated FA (NEFA), as well as NEFA 
from the circulation, can be taken up by the placenta
using FA carriers such as FA translocase (FAT/CD36), 
placental plasma membrane FA-binding protein (p-
FABPpm), or FA transport proteins (FATP), a family of 
proteins comprised of 6 members known as FATP-1 to 
FATP-6. Once FA gain access to the cytosol, they bind to 
FA-binding proteins (FABP) and are thus transferred to 
the fetal circulation. FA can also be oxidized in the pla-
centa or esterified in lipid fractions as, for example, tri-
glycerides in lipid droplet structures  [18] .
 Rat dams injected with 10 or 30 μg radiolabel triglyc-
eride [ 13 H olein] presented at 20 min postinjection the 
same relative percentage of dosed lipids taken up by the 
placenta for the higher as well as the lower dose. How-
ever, the relative percentage of dosed lipids transported 
to the fetus was lower in the dams given more lipids. Even 
though proportionately fewer lipids were transported to 
the fetus when more lipids were given, the absolute 
amount transported was still greater in the dams given the 
30-μg dose  [19] . The maternal FA flux affects the placen-
tal lipid uptake, but the role of placental tissue in moder-
ating this transfer remains to be clarified, especially in 
human studies.
 In GDM compared to normoglycemic pregnancies, a 
higher accumulation of lipid droplets has been classically 
described in histological studies of placental tissue  [20] 
and in trophoblast cells isolated using a density gradient 
 [21] . However, quantification of lipids in the whole pla-
centa is sometimes difficult because of contamination 
from blood. We recently reported a method to isolate pla-
cental lipid droplets for further FA analyses avoiding the 
problem of blood contamination  [22] . A recent study us-
ing in vitro placental explants from healthy pregnancies 
and women with GDM reported that, in pregnancies with 
GDM, a shift in the flux of FA away from oxidation to-
wards the esterification pathway may lead to the accumu-
lation of placental triglycerides  [23] . The mitochondrial 
FA oxidation rate was reduced by  ∼ 20% in placentas from 
women with GDM, contributing to an enhanced triglyc-
eride content within the placenta. Different cellular me-
tabolization of FA in the placental trophoblasts might af-
fect the transfer rate to the fetus; thus, a better knowledge 
of the intracellular metabolism could be of interest.
 It is also important to consider that the functionality 
of the placenta may affect the fetal levels of key nutrients 
such as long-chain polyunsaturated FA (LC-PUFA), do-
cosahexaenoic acid (DHA), or arachidonic acid. Never-
theless, the underlying mechanisms are still unknown. 
The placenta preferentially and selectively transports 
DHA as opposed to other FA, as we demonstrated in vivo 
in healthy pregnant women using FA labeled with stable 
isotopes  [24] . This preferential transfer of LC-PUFA 
across the placenta highlights an important role of this 
organ in differential FA transfer to the fetus  [24, 25] . 
However, an abnormal placental function, as occurs in 
GDM or intrauterine growth retardation, could disturb 
the materno-fetal LC-PUFA transport, with unknown 
consequences for the neurodevelopment of the offspring. 
3rd trimester of gestation  
Hyperlipidemia ensures TG 
and NEFA for the fetus  
Normal pregnancy GDM pregnancy 
Maternal lipolysis 
An altered lipid metabolism is a 
risk factor for macrosomia in GDM 
Physiological insulin 




Fetal fat mass 
 Fig. 1. Maternal lipid adaptations during the third trimester of 
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 Placental Transfer of FA Labeled with Stable 
Isotopes in GDM 
 Because placental lipid pools serve as a relay towards 
transport to the fetus, we studied in humans the in vivo 
placental transfer of FA using labeled FA with stable iso-
topes  [26] . Eleven controls and 9 pregnant women with 
GDM received orally  13 C-palmitic,  13 C-oleic, and  13 C-
linoleic acids and  13 C-docosahexaenoic acid ( 13 C-DHA) 
12 h before an elective caesarean section. Maternal blood 
samples were collected at –12 , –3, –2, and –1 h, at deliv-
ery, and at +1 h (postdelivery), and placenta, venous, and 
arterial cord blood were collected at delivery. 
 As shown in  figure 2 a, we calculated the area under 
the curve (AUC) of the labeled FA in maternal plasma 
prior to the caesarean section (corresponding to time 0). 
We observed a clear difference in AUC between  13 C-
DHA and the rest of the labeled FA in the maternal plas-
ma of GDM subjects. The AUC of  13 C-palmitic,  13 C-ole-
ic, and  13 C-linoleic acid concentrations (μmol    ·    h/l) were 
significantly higher in GDM patients compared to con-
trols, indicating a lower plasma clearance of non-LC-
PUFA in GDM mothers, contributing to maternal hy-
perlipidemia in these subjects. In contrast, the  13 C-DHA 
concentration was significantly lower in the total lipids 
of GDM maternal plasma at the time of delivery, and its 
AUC (μmol    ·    h/l) tended to be reduced in GDM mothers 
(p = 0.057).
 That the maternal hyperlipidemia in GDM is mainly a 
hypertriglyceridemia has been indicated by the higher 
concentration of labeled non-LC-PUFA in the maternal 
plasma triglycerides of GDM patients compared to con-
trols  [26] . In type 2 diabetes, it has been reported that in-
sulin resistance causes high postprandial levels of triglyc-
eride-rich lipoproteins and a prolonged presence in the 
circulation  [27] . However,  13 C-DHA showed a lower rel-
ative incorporation into maternal plasma phospholipids 
in GDM, while a similar incorporation into triglycerides 
was seen  [26] . The lipid fraction in which the FA are es-
terified within maternal plasma is important for their pla-
cental uptake and transfer. A disturbed incorporation of 
DHA in maternal plasma phospholipids could affect the 
plasma clearance of  13 C-DHA and its placental uptake in 
this pathology. These results are in agreement with 
Thomas et al.  [28] , who suggested a potential failure to 
incorporate LC-PUFA into red cell phospholipids in ad-
dition to a defect in placental transport in GDM.
 As occurred in maternal plasma, the concentration of 
labeled DHA was also reduced in total lipids of placental 
tissue from women with GDM. However, for the other 
FA investigated, and specially for palmitic acid, there was 
a tendency towards a higher concentration in GDM pla-
centas, in agreement with the profile in maternal circula-
tion ( fig. 2 b). In vitro studies of BeWo cells (a trophoblast 
cell line) treated with palmitate acid have shown that this 










































 Fig. 2.  a AUC of the  13 C-FA concentration (μmol    ·    h/l) in total lip-
ids of maternal plasma in control and GDM subjects.  b  13 C-FA 
concentration in total lipids of placental tissue.  13 C-PA =  13 C-pal-
mitic acid;  13 C-OA =  13 C-oleic acid;  13 C-LA =  13 C-linoleic acid. 
Control group, n = 11 (except for  13 C-DHA in which n = 6); GDM 
group, n = 9. Results are expressed as means ± SEM.  *  p < 0.05.
p = 0.096 for  13 C-LA and p = 0.057 for  13 C-DHA. Data were taken 




















   
   
   
   
   
   
   
   
   
   
   





















 Placental Determinants of Obesity  Ann Nutr Metab 2014;64:247–253 
DOI: 10.1159/000365028
251
the chromatin structure in a manner that is permissive to 
subsequent increases in inflammatory cytokine gene ex-
pression  [29] .
 The ratio between the  13 C-FA concentration in the pla-
centa and the  13 C-FA concentration in maternal plasma 
was significantly lower for  13 C-DHA in GDM patients 
compared to controls  [26] . These results clearly demon-
strate an impaired placental uptake of LC-PUFA in GDM 
placentas. The ratio between compartments calculated 
using concentration values of  13 C provides information 
on the species of labeled maternal FA that are transported 
by the placenta. Nevertheless, with stable isotope tech-
niques it is also possible to obtain information on  13 C/ 12 C 
enrichment in the sample, which gives information on 
the dilution of the labeled FA in the pool  [26] . The enrich-
ment ratio between the placental and maternal compart-
ments gives information on how many FA, labeled plus 
unlabeled, in the placenta are of maternal origin. Using 
the enrichment ratio between the placenta and maternal 
plasma, we again observed that less  13 C-DHA in the pla-
centa seemed to be maternally derived in GDM patients 
compared to normoglycemic pregnancies (in agreement 
with a lower placental transfer;  fig. 3 a). In contrast, other 
FA tended to show an increased transfer in GDM ( fig. 3 a). 
It is interesting to note that, for essential FA such as lin-
oleic acid, the 100% enrichment ratio indicates that the 
majority of all linoleic acids in placenta are derived from 
maternal plasma, in agreement with the behavior of es-
sential FA. For a conditionally essential FA such as DHA, 
the enrichment ratio in the placenta with respect to ma-
ternal plasma was about 70%; thus, most of the DHA in 
the placenta also appeared to originate in maternal plas-
ma, although this measurement was performed only at 
one time point ( fig. 3 a).
 In cord blood, babies from GDM mothers had de-
creased percentages of  13 C-DHA, both in arterial and ve-
nous cord plasma, while the concentrations of other FA 
tended to be higher in GDM in both cord vessels, promot-
ing fetal macrosomia  [26] . Our results are in agreement 
with observational studies in neonates born to mothers 
with GDM that reported decreased percentages of DHA 
both in cord plasma and in cord red blood cells  [28, 30, 31] . 
The reduced ratio of  13 C-DHA between cord and maternal 
plasma occurred not only when using the concentration 
ratio  [26] but also with the enrichment ratio ( fig. 3 b), which 
is consistent with the lower absolute materno-fetal transfer 
of DHA in GDM. In contrast, the transfer of non-LC-
PUFA was not affected by GDM, tending towards higher 
enrichment values which could promote fetal adiposity in 
the offspring of GDM mothers ( fig. 3 b).
 We could not detect any arterio-venous difference us-
ing concentration or enrichment values [26]; the high 
variance demonstrated by the wide standard errors, and 
therefore inadequate power, plecluded the possibility to 
find differences in fetal accretion between groups [26]. A 
possible limitation of the detection of differences with this 
































































 Fig. 3.  a Ratio of  13 C/ 12 C enrichment in placenta vs. maternal plas-
ma in GDM subjects.  b Ratio of  13 C/ 12 C enrichment in venous cord 
plasma vs. maternal plasma. Results are expressed as means ± 
SEM.  *  p < 0.05. p = 0.187 for 13C-DHA in (b). Data were taken 
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methodology could be that the major differences between 
arteries and veins occur in the NEFA fraction, and the car-
bon 13 determination in NEFA is less precise than in oth-
er lipid fractions due to the low NEFA concentration in 
cord blood, which is difficult to measure accurately. An-
other possibility could be that the 12-hour experimental 
period was inadequate to detect differences in FA uptake 
by fetal tissues since, within that period of 12 h, labeled FA 
have to be distributed in the maternal compartment, taken 
up by the placenta, released to the venous cord blood, re-
distributed among fetal lipoproteins, taken up by fetal tis-
sues, and released again to the arterial cord circulation. 
Nevertheless, the materno-fetal transfer of  13 C-DHA was 
lower in women with GDM treated with insulin compared 
to those treated with diet, and in both groups it was lower 
than in the controls ( fig. 4 a). In contrast, fetuses from the 
treatment groups had similar disturbed placental uptakes 
of DHA compared to controls ( fig. 4 b). Thus, the fetuses 
of GDM women treated with insulin appeared to have 
lower  13 C-DHA levels in cord blood as a result of a path-
way other than placental uptake (most likely a higher fat 
accretion by fetal adipose tissue). It is probable that ma-
ternal hyperglycemia peaks are greater in women treated 
with insulin, thereby producing fetal hyperinsulinemia 
peaks that enhance FA accretion by fetal tissues. We can-
not discount a role for the higher fetal accretion of LC-
PUFA in addition to the impaired placental transfer in 
children from GDM mothers treated with insulin. 
 Concerning the effect of GDM or obesity on placental 
FA carriers, most studies are limited by a small sample 
size, which influences the interpretation of results due to 
the biological variability among placentas. The available 
results on placental lipases in GDM patients are inconclu-
sive, maybe because of the low number of subjects; no 
changes  [8, 32] , increases in EL but not in LPL  [33] , in-
creases in LPL  [34] , and even a reduction in placental LPL 
 [35] in GDM have been reported.
 Concerning placental FA carriers, in obese subjects 
without GDM, FATP-4 was also decreased while FAT/
CD36 was increased  [34] . FATP may contribute to reac-
ylation of PL because of their acyl CoA synthetase activ-
ity  [36] , having an additional role compared to other FA 
carriers. DHA is mainly located in plasma phospholipids, 
and FATP-4 could influence its reacylation in placental 
PL and its movement within the tissue  [37] . Indeed 
FATP4 gene expression has previously been linked to se-
lective placental transfer of n-3 LC-PUFA, since its gene 
expression has been found to correlate with the percent-
age of DHA in cord plasma PL  [38] . FAT is an FA trans-
locase that is coupled to cytosolic FABP as A-FABP. Up-
regulation of A-FABP in obese women with GDM has 
been reported and seems to have an important role in 
trophoblast lipid accumulation  [39] .
 Thus, it is important to control not only glycemia but 
also dyslipidemia in pregnant women to avoid neonatal 
fat accretion and disturbed fetal LC-PUFA, which could 
have implications for neurodevelopment and the later 
risk of obesity.
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 Fig. 4.  a Ratio of the  13 C-DHA concentration in placenta (nmol/g 
 13 C) vs. maternal plasma (μmol/ 13 C) in GDM treated either with diet 
or with insulin.  b Ratio of the  13 C-DHA concentration in venous 
cord plasma vs. maternal plasma. Control group, n = 11; GDM diet 
group, n = 3; GDM insulin group, n = 6. Results are expressed as 
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